Skip to main content
NASDAQ:EVLO

Evelo Biosciences News Headlines

$11.01
0.00 (0.00 %)
(As of 05/14/2021 01:32 PM ET)
Add
Compare
Today's Range
$10.95
$11.23
50-Day Range
$9.43
$13.15
52-Week Range
$3.55
$19.93
Volume5,872 shs
Average Volume254,554 shs
Market Capitalization$587.65 million
P/E RatioN/A
Dividend YieldN/A
Beta1.46

Headlines

Evelo Biosciences (NASDAQ EVLO) News Headlines Today

SourceHeadline
Evelo Biosciences (NASDAQ:EVLO) Shares Up 7.4%Evelo Biosciences (NASDAQ:EVLO) Shares Up 7.4%
americanbankingnews.com - May 13 at 11:58 AM
Evelo Biosciences Presents New Preclinical Data for Extracellular Vesicle Anti-inflammatory Product Candidate EDP2939 at the American Association of Immunologists MeetingEvelo Biosciences Presents New Preclinical Data for Extracellular Vesicle Anti-inflammatory Product Candidate EDP2939 at the American Association of Immunologists Meeting
finance.yahoo.com - May 13 at 9:01 AM
Evelo Biosciences (NASDAQ:EVLO) Shares Gap Up to $9.80Evelo Biosciences (NASDAQ:EVLO) Shares Gap Up to $9.80
americanbankingnews.com - May 12 at 10:58 AM
Evelo Biosciences (NASDAQ:EVLO) Price Target Cut to $13.00 by Analysts at Morgan StanleyEvelo Biosciences (NASDAQ:EVLO) Price Target Cut to $13.00 by Analysts at Morgan Stanley
americanbankingnews.com - May 10 at 9:06 AM
Evelo Biosciences (NASDAQ:EVLO) Shares Gap Down  on Analyst DowngradeEvelo Biosciences (NASDAQ:EVLO) Shares Gap Down on Analyst Downgrade
americanbankingnews.com - May 3 at 12:16 PM
Evelo Biosciences, Inc. (NASDAQ:EVLO) Short Interest Down 17.9% in AprilEvelo Biosciences, Inc. (NASDAQ:EVLO) Short Interest Down 17.9% in April
americanbankingnews.com - May 3 at 7:18 AM
Evelo Biosciences (NASDAQ:EVLO) Posts  Earnings Results, Misses Expectations By $0.04 EPSEvelo Biosciences (NASDAQ:EVLO) Posts Earnings Results, Misses Expectations By $0.04 EPS
americanbankingnews.com - April 30 at 3:58 PM
Evelo Biosciences (NASDAQ:EVLO) Trading Up 5.2%Evelo Biosciences (NASDAQ:EVLO) Trading Up 5.2%
americanbankingnews.com - April 30 at 2:44 PM
Evelo Biosciences, Inc. (EVLO) Q1 2021 Earnings Call TranscriptEvelo Biosciences, Inc. (EVLO) Q1 2021 Earnings Call Transcript
finance.yahoo.com - April 29 at 7:02 PM
Evelo Biosciences, Inc.: Evelo Biosciences Reports First Quarter 2021 Financial Results and Business HighlightsEvelo Biosciences, Inc.: Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights
finanznachrichten.de - April 29 at 9:01 AM
Evelo Biosciences Reports First Quarter 2021 Financial Results and Business HighlightsEvelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights
finance.yahoo.com - April 29 at 9:00 AM
Evelo Biosciences (NASDAQ:EVLO) Trading Down 3.9%Evelo Biosciences (NASDAQ:EVLO) Trading Down 3.9%
americanbankingnews.com - April 28 at 1:58 PM
Evelo Biosciences, Inc. (NASDAQ:EVLO) Given Consensus Recommendation of "Buy" by BrokeragesEvelo Biosciences, Inc. (NASDAQ:EVLO) Given Consensus Recommendation of "Buy" by Brokerages
americanbankingnews.com - April 27 at 4:40 AM
Zacks: Analysts Anticipate Evelo Biosciences, Inc. (NASDAQ:EVLO) Will Post Earnings of -$0.53 Per ShareZacks: Analysts Anticipate Evelo Biosciences, Inc. (NASDAQ:EVLO) Will Post Earnings of -$0.53 Per Share
americanbankingnews.com - April 26 at 10:22 PM
Evelo Biosciences (NASDAQ:EVLO) Shares Gap Up to $11.16Evelo Biosciences (NASDAQ:EVLO) Shares Gap Up to $11.16
americanbankingnews.com - April 23 at 11:37 AM
Evelo Biosciences (EVLO) to Release Earnings on ThursdayEvelo Biosciences (EVLO) to Release Earnings on Thursday
americanbankingnews.com - April 23 at 8:38 AM
Evelo Biosciences to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021Evelo Biosciences to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021
finance.yahoo.com - April 22 at 7:32 AM
Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic DermatitisEvelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis
finance.yahoo.com - April 20 at 6:12 PM
Evelo Biosciences (NASDAQ:EVLO)  Shares Down 7.2% Evelo Biosciences (NASDAQ:EVLO) Shares Down 7.2%
americanbankingnews.com - April 20 at 1:40 PM
Are Institutions Heavily Invested In Evelo Biosciences, Inc.s (NASDAQ:EVLO) Shares?Are Institutions Heavily Invested In Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Shares?
finance.yahoo.com - April 19 at 12:06 PM
Evelo Biosciences (NASDAQ:EVLO) Shares Gap Down to $11.56Evelo Biosciences (NASDAQ:EVLO) Shares Gap Down to $11.56
americanbankingnews.com - April 19 at 12:02 PM
Evelo Biosciences (NASDAQ:EVLO) Upgraded at Jefferies Financial GroupEvelo Biosciences (NASDAQ:EVLO) Upgraded at Jefferies Financial Group
americanbankingnews.com - April 19 at 8:46 AM
Evelo Biosciences Announces Appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to the Board of DirectorsEvelo Biosciences Announces Appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to the Board of Directors
finance.yahoo.com - April 15 at 7:52 AM
Thinking about buying stock in Nuance Communications, GameStop, Evelo Biosciences, Progenity, or Fortress Biotech?Thinking about buying stock in Nuance Communications, GameStop, Evelo Biosciences, Progenity, or Fortress Biotech?
marketwatch.com - April 12 at 1:28 PM
Evelo Biosciences to Present at 20th Annual Needham Virtual Healthcare ConferenceEvelo Biosciences to Present at 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 5 at 9:41 AM
Evelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration to Develop & Commercialize Novel Therapy EDP1815 for Inflammatory Diseases & COVID-19 in Select Developing Markets Serving 1.7 Billion PeopleEvelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration to Develop & Commercialize Novel Therapy EDP1815 for Inflammatory Diseases & COVID-19 in Select Developing Markets Serving 1.7 Billion People
finance.yahoo.com - March 23 at 3:30 AM
Evelo Biosciences, Inc. (EVLO) Q4 2020 Earnings Call TranscriptEvelo Biosciences, Inc. (EVLO) Q4 2020 Earnings Call Transcript
finance.yahoo.com - March 9 at 5:40 PM
Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business HighlightsEvelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
finance.yahoo.com - March 9 at 7:34 AM
Evelo Biosciences to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 9, 2021Evelo Biosciences to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 9, 2021
finance.yahoo.com - March 2 at 8:36 AM
Evelo Biosciences, Inc.: Evelo Biosciences Appoints John A. Hohneker, M.D. to Board of DirectorsEvelo Biosciences, Inc.: Evelo Biosciences Appoints John A. Hohneker, M.D. to Board of Directors
finanznachrichten.de - February 16 at 7:56 AM
Evelo Biosciences Appoints John A. Hohneker, M.D. to Board of DirectorsEvelo Biosciences Appoints John A. Hohneker, M.D. to Board of Directors
finance.yahoo.com - February 16 at 7:56 AM
Evelo Biosciences Reports New Positive Confirmatory Data from Phase 1b Trial of EDP1815 in Atopic DermatitisEvelo Biosciences Reports New Positive Confirmatory Data from Phase 1b Trial of EDP1815 in Atopic Dermatitis
finance.yahoo.com - January 20 at 11:33 AM
Evelo Biosciences, Inc.: Evelo Biosciences Expands Clinical Programs and Provides 2021 Guidance on Key MilestonesEvelo Biosciences, Inc.: Evelo Biosciences Expands Clinical Programs and Provides 2021 Guidance on Key Milestones
finanznachrichten.de - January 7 at 10:36 AM
Evelo Biosciences Expands Clinical Programs and Provides 2021 Guidance on Key MilestonesEvelo Biosciences Expands Clinical Programs and Provides 2021 Guidance on Key Milestones
finance.yahoo.com - January 7 at 10:36 AM
Evelo Biosciences, Inc.: Evelo Biosciences Appoints Industry Veteran Jonathan Zung, Ph.D. as Chief Development OfficerEvelo Biosciences, Inc.: Evelo Biosciences Appoints Industry Veteran Jonathan Zung, Ph.D. as Chief Development Officer
finanznachrichten.de - December 22 at 11:13 PM
Evelo Biosciences Appoints Industry Veteran Jonathan Zung, Ph.D. as Chief Development OfficerEvelo Biosciences Appoints Industry Veteran Jonathan Zung, Ph.D. as Chief Development Officer
finance.yahoo.com - December 21 at 7:41 AM
Insider Buying: The Evelo Biosciences, Inc. (NASDAQ:EVLO) Independent Chairman Just Bought 77% More SharesInsider Buying: The Evelo Biosciences, Inc. (NASDAQ:EVLO) Independent Chairman Just Bought 77% More Shares
finance.yahoo.com - December 15 at 7:45 AM
Stock Alert: Evelo Biosciences Jumps 43%Stock Alert: Evelo Biosciences Jumps 43%
nasdaq.com - December 14 at 3:37 PM
Evelo Biosciences, Inc.: Evelo Biosciences Reports Positive Topline Clinical Data in Phase 1b Trial of EDP1815 in Atopic DermatitisEvelo Biosciences, Inc.: Evelo Biosciences Reports Positive Topline Clinical Data in Phase 1b Trial of EDP1815 in Atopic Dermatitis
finanznachrichten.de - December 10 at 10:52 PM
Evelo Biosciences Announces New Clinical Candidate in Oncology and Presents Additional Interim Data from Phase 1/2 Clinical Trial of EDP1503 in Patients with Triple-Negative Breast CancerEvelo Biosciences Announces New Clinical Candidate in Oncology and Presents Additional Interim Data from Phase 1/2 Clinical Trial of EDP1503 in Patients with Triple-Negative Breast Cancer
finance.yahoo.com - December 9 at 5:23 PM
Evelo Biosciences Reports Positive Topline Clinical Data in Phase 1b Trial of EDP1815 in Atopic DermatitisEvelo Biosciences Reports Positive Topline Clinical Data in Phase 1b Trial of EDP1815 in Atopic Dermatitis
finance.yahoo.com - December 9 at 7:35 AM
Evelo Biosciences, Inc.: Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of PsoriasisEvelo Biosciences, Inc.: Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis
finanznachrichten.de - December 4 at 11:37 PM
Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of PsoriasisEvelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis
finance.yahoo.com - December 3 at 9:08 AM
News for Evelo Biosciences Inc Registered ShsNews for Evelo Biosciences Inc Registered Shs
markets.businessinsider.com - November 18 at 10:27 PM
Evelo Biosciences: Clinical Data Coming SoonEvelo Biosciences: Clinical Data Coming Soon
seekingalpha.com - November 10 at 1:29 PM
What You Need To Know About Evelo Biosciences, Inc.s (NASDAQ:EVLO) Investor CompositionWhat You Need To Know About Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Investor Composition
finance.yahoo.com - November 10 at 1:29 PM
Evelo Biosciences Presents New Preclinical Data for Anti-Tumor Effects of Orally Delivered Microbial Extracellular Vesicles at the SITC 35th Anniversary Annual MeetingEvelo Biosciences Presents New Preclinical Data for Anti-Tumor Effects of Orally Delivered Microbial Extracellular Vesicles at the SITC 35th Anniversary Annual Meeting
finance.yahoo.com - November 9 at 12:27 PM
Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q3 2020 Results - Earnings Call TranscriptEvelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 1 at 8:10 AM
Evelo Biosciences, Inc.: Evelo Biosciences Reports Third Quarter 2020 Financial Results and Business HighlightsEvelo Biosciences, Inc.: Evelo Biosciences Reports Third Quarter 2020 Financial Results and Business Highlights
finanznachrichten.de - October 29 at 8:59 AM
Evelo Biosciences, Inc. to Host Earnings CallEvelo Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - October 29 at 8:59 AM
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.